Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an analysis of Celsius Stock, ELF Stock, and CMG Stock

3 extracted signals · 3 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor11 Nov 2025, 00:53 UTC
Video preview for Friends! In this video, I'm going to do an analysis of Celsius Stock, ELF Stock, and CMG Stock
Signals
3
Eligible signals in this source
Open
0
Still being tracked
Resolved
3
Evaluable outcomes
Successful
0
Canonical correct result
Failed
3
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

The video discusses three stocks, CELH, ELF and CMG, trading near their 52-week lows. CELH, currently priced at $41.52, has experienced a 35% drop over the last month. The video identifies concerns about CELH's Alani Nu distribution agreement affecting revenues in the next 1-2 quarters, plus organic growth in the CELH brand only at 13% year-over-year. International growth has only grown 24%. It also mentions analyst concerns, but notes the valuation is more interesting now. For ELF, it trades at $73.74, a 40% drop over 2-3 days. It beat earnings per share expectations, despite slight miss on revenue. Guidance was disappointing due to China tariffs. Rhode acquisition should contribute 13% revenue growth forecast. The company expects sequentially gross margin improvements in the second half of the year. Rhode's expected contribution, analyst is less optimistic. ELFs organic is 3-4% currently. The CEO expects revenue of 1.55 billion to 1.57 billion. The stock needs Rhodes acquisition to hit growth for the quarters ahead. For Chipotle, it trades at $30.59 a 50% decline year to date. It slightly missed revenue and the company said consumer spending is impacting it because of spending less. They won't be doing discouting but will have menu innovation. But its core earnings is still good. Finally, the author notes that the given advice isn't financial.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    3 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.